Treace Medical Concepts, Inc. (TMCI) Misses Q2 EPS by 5c, reaffirms guidance

Treace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q2 EPS of ($0.34), $0.05 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $44.5 million versus the consensus estimate of $43 million.

GUIDANCE:

Treace Medical Concepts, Inc. sees FY2024 revenue of $201-211 million, versus the consensus of $205.5 million, representing growth of 7% to 13%, compared to full-year 2023.

The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.

For earnings history and earnings-related data on Treace Medical Concepts, Inc. (TMCI) click here.

You May Also Be Interested In

• ConAgra Brands (CAG) Tops Q4 EPS by 1c, Beats on Revenue; Offers FY EPS Guidance
• Kratos Defense & Security (KTOS) Reiterated at Buy by Stifel on ~400M Funding Disclosure
• Phoenix Education Partners, Inc. (PXED) Misses Q3 EPS by 14c; Offers Outlook